Boston Bio Systems Ltd
₹ 8.09
4.93%
13 Jun
- close price
About
Incorporated in 1995, Boston Bio Systems
Ltd is in the business of trading in goods
e.g. Medical equipment, testing kits,
instruments etc.[1]
Key Points
- Market Cap ₹ 5.66 Cr.
- Current Price ₹ 8.09
- High / Low ₹ 22.0 / 6.53
- Stock P/E
- Book Value ₹ 8.43
- Dividend Yield 0.00 %
- ROCE -6.18 %
- ROE -8.91 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.96 times its book value
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 2.14%
- Company has a low return on equity of -3.58% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 5,533 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.12 | 0.15 | 0.05 | 0.06 | 1.50 | 0.53 | 0.70 | 0.00 | 0.00 | 0.00 | 0.19 | |
| 0.02 | 0.27 | 0.16 | 0.05 | 0.06 | 1.50 | 0.53 | 0.70 | 0.00 | 0.00 | 0.14 | 0.74 | |
| Operating Profit | -0.02 | -0.15 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.14 | -0.55 |
| OPM % | -125.00% | -6.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -289.47% | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.02 | -0.15 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.14 | -0.55 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |||||||
| -0.02 | -0.15 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.14 | -0.55 | |
| EPS in Rs | -0.03 | -0.21 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.20 | -0.79 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -293% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -4% |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -4% |
| Last Year: | -9% |
Balance Sheet
Figures in Rs. Crores
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 |
| Reserves | -0.24 | -0.40 | -0.40 | -0.40 | -0.40 | -0.40 | -0.40 | -0.40 | -0.41 | -0.41 | -0.55 | -1.10 |
| 1.14 | 0.14 | 0.12 | 0.12 | 0.12 | 0.87 | 0.87 | 0.87 | 0.87 | 0.87 | 0.87 | 4.59 | |
| 0.00 | 0.00 | -0.01 | -0.01 | -0.01 | 1.46 | 1.90 | 2.60 | 3.11 | 3.11 | 3.25 | 4.41 | |
| Total Liabilities | 7.90 | 6.74 | 6.71 | 6.71 | 6.71 | 8.93 | 9.37 | 10.07 | 10.57 | 10.57 | 10.57 | 14.90 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 7.90 | 6.74 | 6.71 | 6.71 | 6.71 | 8.93 | 9.37 | 10.07 | 10.57 | 10.57 | 10.57 | 14.90 | |
| Total Assets | 7.90 | 6.74 | 6.71 | 6.71 | 6.71 | 8.93 | 9.37 | 10.07 | 10.57 | 10.57 | 10.57 | 14.90 |
Cash Flows
Figures in Rs. Crores
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 1.00 | 0.00 | 0.00 | 0.97 | -0.03 | -0.02 | 0.13 | 0.00 | 0.00 | 0.00 | -4.58 | |
| 0.00 | 0.00 | 0.00 | 0.00 | -0.91 | 0.00 | 0.00 | -0.08 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.00 | -1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.57 | |
| Net Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | -0.03 | -0.02 | 0.05 | 0.00 | 0.00 | 0.00 | -0.01 |
Ratios
Figures in Rs. Crores
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 0.00 | 362.57 | 1,342.92 | 1,308.79 | 5,532.63 | ||||
| Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | 11.59 | |||||||
| Days Payable | 1,488.97 | |||||||||||
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 362.57 | 1,342.92 | -168.60 | 5,532.63 | ||||
| Working Capital Days | 0.00 | 0.00 | 0.00 | 5,475.00 | 408.80 | 1,177.64 | 844.71 | -979.74 | ||||
| ROCE % | -0.25% | -2.05% | -0.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1.89% | -6.18% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2 Jun - Newspaper Intimation under Regulation 47 of SEBI (LODR) Regulations, 2015 for your reference.
-
Non-Applicability Of Annual Secretarial Compliance Report For The Year Ended 31St March, 2025 Under Regulation 24A Of The SEBI (LODR) Regulations, 2015
30 May - Exempted from Annual Secretarial Compliance Report for FY 2024-25 due to capital and net worth limits.
- Please Find Enclosed Herewith Audited Results Of The Company For The Financial Year Ended 31St March, 2025 30 May
-
Board Meeting Outcome for Please Find Enclosed Herewith Outcome Of The Board Meeting For Year Ended 31St March, 2025
30 May - Audited standalone financial results for FY 2025 approved; reported net loss of Rs. 54.73 lakhs.
-
Board Meeting Intimation for Consider And Approve Audited Financial Results Of The Company For The Quarter And Year Ended On 31St March, 2025.
21 May - Board meeting on 30 May 2025 to approve audited results for quarter/year ended 31 March 2025.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2000
from bse
-
Financial Year 1999
from bse
Business Overview:[1]
BBSL specializes in jobwork for herbal and health-related products for formulation companies. Company also has plans to enter the medical field which includes the sales and servicing of medical equipment